Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (44)	6/21/2000 4:29:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 724

an example of "trickle down"...... www2.marketwatch.com What subsector is hot? Genomics!! Does genomics require shakers? Does it require ultralow freezers? What other subsector is hot? Proteomics!! dgibt.com Sigh. I must be missing something....... Wednesday, June 21, 2000 --3:07 pm Analyst bullish on BIOI BioSource International Inc. (BIOI: news, msgs) is soaring 5 11/16, or 50.6 percent, to 16 15/16. Paul Knight, an analyst with Thomas Weisel, issued a note this morning stating that a survey by the firm found that exports of mass spectrometers rose 40 percent in March, a bullish sign for BioSource, which produces immunological reagents, test kits and oligonucleotides used in biomedical research. "We believe BioSurce is a primary beneficiary of this protein demand as about 60 percent of the company is in protein," Knight's note reads. Knight theorizes that BioSource could prosper as new genes are discovered and drug development accelerates in genomics. Knight, who has a 12-month price target of $19.25 on the stock, said BioSource has indicated that demand for its synthetic DNA products is at its highest level ever. He also notes that better-than-expected growth could result from pending orders for the company's Beta-Amaloid product, a protein molecule linked to Alzheimer's disease, which was introduced in February. The Camarillo, Calif., firm declined comment on the price movement. Knight initiated coverage of BioSource with a "strong buy" rating on June 14.